Molzym announces FDA Breakthrough Device Designation for its molecular diagnostic test system
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Scientific, technological and communications excellence has been celebrated at the Virtual Cancer and Immunology Research Summit, with Logos Biosystems, INTEGRA Biosciences and Sartorius among those recognized
UN3373 compliant sample packaging solution
Discover how collaborative research between big pharma and academia is using the latest proteomics platforms to revolutionize drug discovery
Explore topics from HRIM-MS for enhancing structural characterization to microbial monitoring, in situ hybridization and advances in fragrance profiling
Discover how to increase precision and reduce throughput time of your routine electrolyte analyses
Learn how COVID-19 serology testing may inform long-term vaccination strategy and influence short-term prioritization and delivery
The findings could lead to faster, more secure memory storage, in the form of antiferromagnetic bits
Company rapidly expanding commercial operations to enable more researchers to extract higher yields of DNA and RNA from FFPE samples in one hour with minimal hands-on time
Catch up on this expert webinar to discover the customizable screening service helping to drive the validation of novel cancer therapies
Watch this on-demand webinar to learn about the commercial responsibilities of new in vitro diagnostic regulations
Ongoing recruitment strengthens teams in all areas of integrated discovery
In this guest editorial, explore how artificial intelligence is becoming a powerful tool for drug discovery
Infectious disease expert shares how robust LC columns are facilitating the analysis of complex pathogen samples
Dr. Frank Peacock discusses the impact of delayed care in the ED setting, the power of high-sensitivity troponin assays, and the value of point of care